AAAC A.I CyberSecurity Scoring
26/03/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Allergan Aesthetics, an AbbVie Company in 2026.
No incidents recorded for Allergan Aesthetics, an AbbVie Company in 2026.
No incidents recorded for Allergan Aesthetics, an AbbVie Company in 2026.
We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines
Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.
Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc
We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms
For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]
At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.
Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals
Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com
We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.
Latest updates, reports, and threat intel affecting the global network.
Allergan Aesthetics will showcase 17 ASDS abstracts, with three in the Cosmetic 'Top Ten', plus Phase 3 trenibotulinumtoxinE and a Phase 4...
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the seventh annual BOTOX® Cosmetic Day will take place on Wednesday,...
Allergan Aesthetics showcases multimodal AA Signature™ treatment at AMWC Dubai, following successful launch in 25 countries.
Allergan Aesthetics expands SKINVIVE, the longest-lasting hydrating injectable, to 57 markets globally. Research shows 94% seek facial skin...
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced a new chapter for BOTOX® Cosmetic with the debut of "The One & Only"...
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announces the return of JUVÉDERM® Day, Wednesday, August 20.
... ** INVESTIGATION CLOSED **. ** WE ARE NO LONGER INVESTIGATING THIS COMPANY **. WHAT HAPPENED? On May 21, 2025, Allergan Aesthetics...
Pharma cos and docs say medical conferences have declined since March after UCPMP was notified.
Explore different areas of our business through immersive experiences like our EXCEL externship, or longer-term, paid opportunities such as our internships and...
VaahCMS versions 2.0.0 through 2.3.4 contain a malicious obfuscated JavaScript payload embedded in the Blade template responsible for rendering security OTP emails, allowing remote attackers to execute unauthorized code in any browser that renders the affected email template with JavaScript enabled. The payload establishes a WebSocket connection to a hardcoded command-and-control endpoint, installs a password-field keylogger using MutationObserver to capture dynamically added inputs, scrapes WhatsApp Web DOM content, and accepts remote commands to redirect or overwrite the rendered page.
undici does not validate the type property of a duck-typed blob-like request body before using it as the Content-Type header on the HTTP/1.1 dispatcher. In undici before 6.28.0, from 7.0.0 up to before 7.29.0, and from 8.0.0 up to before 8.9.0, an application that passes a hand-rolled blob-like body (via request, stream, pipeline, or dispatch) whose type is derived from untrusted input allows an attacker to inject CRLF sequences and append arbitrary HTTP headers, potentially smuggling a second request past the upstream. Native Blob objects are safe because their constructor strips CRLF from the type, and fetch is unaffected because it validates headers, but ecosystem libraries that build duck-typed blob shapes from user input can reach the vulnerable path. This is the same defect class as CVE-2022-35948 and CVE-2026-1527, on a header sink that the earlier fixes did not cover. The issue is fixed in undici 6.28.0, 7.29.0, and 8.9.0.
undici's cache interceptor mishandles optional whitespace placed around the equals sign of a qualified no-cache or private Cache-Control directive. In undici from 7.0.0 up to before 7.29.0 and from 8.0.0 up to before 8.9.0, the parser either drops the directive or stores a field name with literal quote characters, so the cache decision fails to recognize the qualification and the response is stored. In shared-cache mode, this lets a response containing one user's authenticated data be served from cache to a later caller, including an unauthenticated one, when both requests resolve to the same cache key. It affects applications that enable the cache interceptor in shared mode, forward Authorization headers upstream, and receive cacheable responses with qualified directives padded with whitespace around the equals sign. This is the whitespace-around-equals variant that the fix for CVE-2026-9678 did not normalize, and it is fixed in undici 7.29.0 and 8.9.0.
kishan0725 Hospital Management System 4.0 is vulnerable to SQL Injection in check_availability.php via the parameters emailid and email.
kishan0725 Hospital Management System 4.0 is vulnerable to SQL Injection in /doctor/edit-patient.php?editid=1.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.